Suppr超能文献

替莫唑胺治疗后 MEN1 泌乳素分泌性垂体癌的长期控制。

Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.

机构信息

Department of endocrinology and reference center for rare pituitary diseases, hôpital Timone, assistance publique hôpitaux de Marseille, Aix-Marseille université, 13284 Marseille, France.

出版信息

Ann Endocrinol (Paris). 2012 Jun;73(3):225-9. doi: 10.1016/j.ando.2012.03.001. Epub 2012 Apr 20.

Abstract

We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal. Initial presentation was pituitary apoplexy leading to surgery. Dopamine agonists and radiotherapy allowed control of prolactin secretion and pituitary remnant. Metastasis appeared 10 years after initial presentation, leading to the diagnosis of pituitary carcinoma. At that time, dopamine agonists were no more effective; temozolomide, an oral alkylating agent, was administered for 24 cycles, and allowed decrease of the volume of the pituitary lesion and metastases. The patient is still currently followed in our department, 3 years after temozolomide withdrawal: prolactin level and pituitary tumor volume remain controlled without any chemotherapy. To our knowledge, this is the first case of MEN1 prolactin secreting pituitary carcinoma controlled long-term after temozolomide discontinuation.

摘要

我们在此报告一例罕见病例,一名年轻男性患者表现为多发性内分泌腺瘤病 1 型 - 泌乳素分泌性垂体癌,在停用替莫唑胺后长期得到控制。最初的表现为垂体卒中,导致手术。多巴胺激动剂和放疗可控制泌乳素的分泌和垂体残余。10 年后出现转移,导致垂体癌的诊断。此时,多巴胺激动剂已不再有效;替莫唑胺,一种口服烷化剂,已使用 24 个周期,可使垂体病变和转移灶的体积缩小。患者在停用替莫唑胺后 3 年仍在我科接受随访:泌乳素水平和垂体肿瘤体积仍得到控制,无需任何化疗。据我们所知,这是首例多发性内分泌腺瘤病 1 型泌乳素分泌性垂体癌在停用替莫唑胺后长期得到控制的病例。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验